[go: up one dir, main page]

AR026986A1 - Implante farmaceutico con contenido de componentes de liberacion inmediata y liberacion sostenida y metodos de administracion - Google Patents

Implante farmaceutico con contenido de componentes de liberacion inmediata y liberacion sostenida y metodos de administracion

Info

Publication number
AR026986A1
AR026986A1 ARP000106698A ARP000106698A AR026986A1 AR 026986 A1 AR026986 A1 AR 026986A1 AR P000106698 A ARP000106698 A AR P000106698A AR P000106698 A ARP000106698 A AR P000106698A AR 026986 A1 AR026986 A1 AR 026986A1
Authority
AR
Argentina
Prior art keywords
release
implant
sustained release
sustained
administration
Prior art date
Application number
ARP000106698A
Other languages
English (en)
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of AR026986A1 publication Critical patent/AR026986A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un implante farmacéutico para administrar una sustancia biologicamente activa se compone de un componente de liberacion inmediata, que preferentementecontiene un agente desintegrante y un componente de liberacion sostenida. El implante de la presente invencion confiere flexibilidad para regular la liberacionsostenida. El implante de la presente invencion confiere flexibilidad para regular la liberacion del medicamento y se puede producir uncomienzo de la accionmás rápido junto con una liberacion sostenida a largo plazo. La velocidad de liberacion de la sustancia biologicamente activa puede ser ajustada controlandolas cantidades relativas del componente de liberacion inmediata y del componente de liberacion sostenida.
ARP000106698A 1999-12-16 2000-12-15 Implante farmaceutico con contenido de componentes de liberacion inmediata y liberacion sostenida y metodos de administracion AR026986A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17121599P 1999-12-16 1999-12-16

Publications (1)

Publication Number Publication Date
AR026986A1 true AR026986A1 (es) 2003-03-05

Family

ID=22622955

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106698A AR026986A1 (es) 1999-12-16 2000-12-15 Implante farmaceutico con contenido de componentes de liberacion inmediata y liberacion sostenida y metodos de administracion

Country Status (12)

Country Link
US (1) US20020131988A1 (es)
EP (1) EP1237556A2 (es)
JP (1) JP2003517014A (es)
KR (1) KR100715748B1 (es)
AR (1) AR026986A1 (es)
AU (1) AU783538B2 (es)
BR (1) BR0016012A (es)
CA (1) CA2391957A1 (es)
MX (1) MXPA02005911A (es)
NZ (1) NZ519575A (es)
WO (1) WO2001043749A2 (es)
ZA (1) ZA200204352B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953586B1 (en) * 2000-06-08 2005-10-11 Ivy Animal Health, Inc. Growth promoting pharmaceutical implant
AUPR602501A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release pharmaceutical composition
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
GB2404865B (en) * 2001-09-11 2005-09-28 Caretek Medical Ltd Novel drug delivery technology
DE10164510A1 (de) * 2001-12-20 2003-07-10 Schering Ag Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
NZ534317A (en) * 2002-01-24 2006-06-30 Smart Drug Systems Inc Sustained release pharmaceutical composition carried in or on silicone support material
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
EP3326617A1 (en) 2004-06-12 2018-05-30 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
WO2006078320A2 (en) 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US20080102123A1 (en) * 2006-10-27 2008-05-01 Schachter Deborah M Self-gelling tunable drug delivery system
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
JP5502751B2 (ja) 2007-12-20 2014-05-28 エボニック コーポレイション 低残留溶媒濃度を有する微粒子を調製するためのプロセス
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
US20100317629A1 (en) * 2009-06-11 2010-12-16 Medtronic, Inc. Dissolvable pharmaceutical implant
CN102917693B (zh) * 2009-09-17 2015-05-20 赢创有限公司 释放特征不同的植入装置及制造和使用该装置的方法
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8758798B2 (en) 2010-03-24 2014-06-24 Covidien Lp Therapeutic implant
US8758799B2 (en) * 2010-03-24 2014-06-24 Covidien Lp Therapeutic implant
US8758800B2 (en) * 2010-03-24 2014-06-24 Covidien Lp Therapeutic implant
US20110312927A1 (en) * 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US9211175B2 (en) 2010-07-08 2015-12-15 Covidien Lp Self-detachable medical devices
FR2962646B1 (fr) 2010-07-16 2012-06-22 Sofradim Production Prothese avec element radio-opaque
US9572907B2 (en) 2010-10-01 2017-02-21 Covidien Lp Implantable polymeric films
US8920867B2 (en) 2010-10-19 2014-12-30 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
US8632839B2 (en) 2010-10-19 2014-01-21 Covidien Lp Methods of forming self-supporting films for delivery of therapeutic agents
US9861590B2 (en) 2010-10-19 2018-01-09 Covidien Lp Self-supporting films for delivery of therapeutic agents
US9144634B2 (en) 2011-01-14 2015-09-29 Covidien Lp Medical device with intrapore films
FR2977790B1 (fr) 2011-07-13 2013-07-19 Sofradim Production Prothese pour hernie ombilicale
US8579924B2 (en) 2011-07-26 2013-11-12 Covidien Lp Implantable devices including a mesh and a pivotable film
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9782957B2 (en) 2011-08-24 2017-10-10 Covidien Lp Medical device films
US9179994B2 (en) 2011-10-25 2015-11-10 Covidien Lp Implantable film/mesh composite
US8932621B2 (en) 2011-10-25 2015-01-13 Covidien Lp Implantable film/mesh composite
US9005308B2 (en) 2011-10-25 2015-04-14 Covidien Lp Implantable film/mesh composite for passage of tissue therebetween
US10206769B2 (en) 2012-03-30 2019-02-19 Covidien Lp Implantable devices including a film providing folding characteristics
FR2992662B1 (fr) 2012-06-28 2014-08-08 Sofradim Production Tricot avec picots
FR2992547B1 (fr) 2012-06-29 2015-04-24 Sofradim Production Prothese pour hernie
MX2017016823A (es) 2015-06-22 2018-03-12 Lipocine Inc Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados.
WO2017105512A1 (en) * 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
CN110251737A (zh) * 2019-08-06 2019-09-20 湖南优感觉生物科技有限公司 一种添加了玻尿酸的乳胶避孕套
EP4000688B1 (en) 2020-11-19 2025-11-05 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of trenbolone acetate having a definite particle size distribution
EP4001289B1 (en) 2020-11-19 2023-05-03 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of trenbolone and/or trenbolone acetate
ES3032945T3 (en) 2020-11-19 2025-07-29 Fis Fabbrica Italiana Sintetici Spa Process for the preparation of trenbolone acetate having a definite particle size distribution and a irregular hexagon plates crystal habit
LT4037666T (lt) 2020-12-08 2024-06-10 Ruminant Biotech Corp Limited Medžiagų pristatymo gyvūnams prietaisų ir būdų patobulinimai

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3417182A (en) * 1963-03-25 1968-12-17 Upjohn Co Compositions and treatments using 6-methyl - 16 - methylene - 17alpha - hydroxy-4,6-pregnadiene-3,20-dione 17-acetate
US3737521A (en) * 1970-12-09 1973-06-05 Goodrich Co B F Formulation for sustained release of a biological agent
FR2271832A1 (en) * 1974-05-22 1975-12-19 Dynachim Sarl Compsns. contg. sex hormones and their esters - for improving wt. gain in meat animals
FR2290906A1 (fr) * 1974-11-13 1976-06-11 Dick Pierre Nouvelles associations hormonales synergisees pour l'implantation d'animaux de boucherie
IE56979B1 (en) * 1984-02-14 1992-02-26 Drug Systems Res & Dev Subcutaneous implant
US5288496A (en) * 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
US5227167A (en) * 1991-06-11 1993-07-13 Alza Corporation Long-term delivery device including hydrophobic loading dose
US7767708B2 (en) * 1998-11-04 2010-08-03 Schering-Plough Animal Health Corp. Growth stimulant compositions
BR9914996A (pt) * 1998-11-04 2001-07-10 Schering Corp Composições estimulantes de crescimento melhorado
US6498153B1 (en) * 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition

Also Published As

Publication number Publication date
BR0016012A (pt) 2002-07-23
KR20020068376A (ko) 2002-08-27
ZA200204352B (en) 2003-10-01
KR100715748B1 (ko) 2007-05-08
AU783538B2 (en) 2005-11-03
JP2003517014A (ja) 2003-05-20
US20020131988A1 (en) 2002-09-19
MXPA02005911A (es) 2002-10-23
WO2001043749A3 (en) 2002-01-03
AU1756101A (en) 2001-06-25
WO2001043749A2 (en) 2001-06-21
EP1237556A2 (en) 2002-09-11
CA2391957A1 (en) 2001-06-21
NZ519575A (en) 2003-11-28

Similar Documents

Publication Publication Date Title
AR026986A1 (es) Implante farmaceutico con contenido de componentes de liberacion inmediata y liberacion sostenida y metodos de administracion
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
NZ336511A (en) Treating prostatic diseases using delayed and/or sustained release formulations of activated vitamin D
NO20061859L (no) OROS Push Stick for kontrollert tilforsel av aktive midler
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
BRPI0311701B8 (pt) formulação farmacêutica de dosagem multiparticulada revestida com liberação controlada de lamotrigina
PA8526101A1 (es) Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento
BRPI0518582A2 (pt) implante para liberaÇço de medicamento intra-ocular
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
BR0315700A (pt) Dispositivo médico implantável que incorpora rapamicina deuterada para a aplicação controlada da mesma
AU1079701A (en) Oral transmucosal drug dosage using solid solution
BR0312007A (pt) Controle de taxa de administração transcutânea usando composições farmacêuticas amorfas
IL190838A0 (en) Intranasal administration of rapid acting insulin
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
NO20026171L (no) Topiske farmasöytiske formuleringer og fremgangsmåter for behandling
ES2193159T3 (es) Una formulacion de factor de coagulacion viii.
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
ES2139002T3 (es) Terapia medicamentosa citotoxica.
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
AU1046302A (en) Transdermal therapeutic system
WO2002034267A8 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
WO2002060410A3 (en) Methods for sustained release local delivery of drugs for ablation of unwanted tissue
RU2007138867A (ru) Режимы дозирования транс-кломифена
SV2006001916A (es) Formulaciones farmaceuticas transdermales

Legal Events

Date Code Title Description
FB Suspension of granting procedure